SecBot SecBot
8-K ·Filed Oct 8, 2026

RDGL

VIVOS INC
NEUTRAL
Impact 3/10
Horizonweeks Processed18d 6h ago SEC0001493152-26-046354
Killer combo: Material agreement + unregistered equity (likely PIPE/convertible)
Actionable Insight • Neutral

Monitor for any future conversion of the Series D Preferred into common stock at $0.08 per share, which could create significant dilution if exercised. The $250,000 cash infusion is modest and likely funds working capital. No financial statements were filed, so assess the company's cash runway from the next quarterly report.

DirectionNeutral
Confidencehigh
Horizonweeks
Latest settled — T+5d
RDGL ▲ +0.91% at T+5d
NEUTRAL call +0.91% · α vs SPY +2.87% · entry $0.0486 → $0.0490
Next anchor: T+20d in 9d
Latest observation: T+10 -9.63% FF3 residual α
Entry = T+0 close
Oct 8, 2026
via day close
T+1d
-1.15%
call -1.15% · α -1.09%
$0.0480
settled 18d ago
T+5d
+0.91%
call +0.91% · α +2.87%
$0.0490
settled 12d ago
T+20d
Pending
in 9d
T+60d
Pending
in 2mo

Price Chart

Loading chart...

Executive Summary

Vivos Inc. entered into a Stock Purchase and Exchange Agreement with board member Carl Cadwell, who purchased 250,000 shares of newly created Series D Convertible Preferred Stock for $250,000 and exchanged all 385,302 outstanding shares of Series C Preferred for Series D Preferred. The Series C Preferred was subsequently eliminated via a Certificate of Elimination, simplifying the capital structure. The transaction provides $250,000 in new cash and consolidates preferred equity into a single series with a $0.08 conversion price.

Key Financial Metrics

Offering Size
$250.0K

Key Facts

  • Board member Carl Cadwell purchased 250,000 Series D Preferred shares for $250,000 ($1.00 per share)
  • Cadwell exchanged 385,302 Series C Preferred shares for an equal number of Series D Preferred shares
  • All Series C Preferred shares were eliminated; no Series C shares remain outstanding
  • 635,302 Series D Preferred shares outstanding post-transaction with a conversion price of $0.08 per share
  • Series D Preferred has a stated value of $1.00 per share; authorized at 1.0 million shares out of 10.0 million total preferred shares
  • The $250,000 purchase price was paid via wire transfer on October 1, 2026, prior to the closing date
  • Shares were issued in a private placement exempt from registration under Section 4(a)(2) and Rule 506(b) of Regulation D

Financial Impact

The company received $250,000 in new cash from the Series D purchase. The exchange of Series C for Series D Preferred is a like-kind swap with no change in stated value ($385,302). The elimination of Series C Preferred simplifies the capital structure but does not change total preferred equity outstanding.

cashpreferred equitydilution potential

Risk Factors

  • The Series D Preferred carries a conversion price of $0.08 per share, which could result in substantial dilution to common shareholders if converted
  • The company's securities are not listed on any exchange (trading symbol N/A), limiting liquidity and price discovery
  • No financial data was provided in this filing, making it impossible to assess the company's current financial health or cash runway

Investment Themes

Healthcare & Medical Devices

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001493152-26-046354
Exhibit: ex10-1.htm0001493152-26-046354
Exhibit: ex3-1.htm0001493152-26-046354
Document: 0001493152-26-046354-index-headers.html0001493152-26-046354
Document: 0001493152-26-046354-index.html0001493152-26-046354
Document: 0001493152-26-046354.txt0001493152-26-046354

US Market Status

Market Closed — Opens Wed (10h 11m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Oct 8, 2026